AbbVie Inc. (ABBV) Inventory
The inventory for AbbVie Inc. (ABBV) is $4.95 Billion with a year-over-year change of +18.42%. Inventory includes raw materials, work-in-progress, and finished goods held by a company for sale or for use in production.
ABBV Inventory Chart
Current Inventory
$4.95B
$4.95 Billion
Year-over-Year Change
+18.42%
vs. $4.18B prior year
Historical Data
16
Years of data available
Annual Inventory History
| Year | Inventory | YoY Change | % Change |
|---|---|---|---|
| 2025 | $4.95B | +$770.00M | +18.42% |
| 2024 | $4.18B | +$82.00M | +2.00% |
| 2023 | $4.10B | +$520.00M | +14.53% |
| 2022 | $3.58B | +$451.00M | +14.42% |
| 2021 | $3.13B | $-182.00M | -5.50% |
| 2020 | $3.31B | +$1.50B | +82.57% |
| 2019 | $1.81B | +$208.00M | +12.96% |
| 2018 | $1.60B | +$0 | 0.00% |
| 2017 | $1.60B | +$161.00M | +11.15% |
| 2016 | $1.44B | $-275.00M | -16.00% |
| 2015 | $1.72B | +$595.00M | +52.94% |
| 2014 | $1.12B | $-26.00M | -2.26% |
| 2013 | $1.15B | +$59.00M | +5.41% |
| 2012 | $1.09B | +$219.00M | +25.11% |
| 2011 | $872.00M | +$35.73M | +4.27% |
| 2010 | $836.27M | — | — |
About AbbVie Inc.
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Robert A. Michael